Search for a trial

EuroSkinGraft - Novomaix phase II
A phase 2, intra-patient randomised controlled multicentre international study to evaluate the efficacy of an acellular dermal template Novomaix for the treatment of full thickness skin defects.

To test an acellular dermal template (Novomaix) in human patients in need of full thickness skin defect coverage and to compare the results with those obtained after conventional STSG. The main goals are to study the efficacy and scar quality after…

Efficacy of Verapamil/ Verapamil-Kenacort injection versus Kenacort injection in Scar Treatment

Scar volume and POSAS score will be measured in the Verapamil group, these will be compared to the scar volume and POSAS score in the Kenacort+Verapamil group and the Kenacort group. In addition, complications/ adverse effects will be reported.

Perforator based interposition flaps for sustainable release of scar contractures: a reliable, simple and versatile technique.

A randomised controlled multcenter trial is performed to evaluate the perforator-based interposition plasty in comparison to full thichness grafts for scar contracture releases.

A phase II study of ARA 290 as therapeutic strategy in no-option critical limb ischemia patients.

A proof of concept study to test whether ARA 290 improves wound healing and reduces neuropathic pain in no-option patients with CLI

MELAMAG Trial: SentiMAG Melanoma - Sentinel Node Biopsy using Magnetic Nanoparticles: A prospective multicentre feasibility non-randomised clinical trial to compare sentinel node biopsy using magnetic nanoparticles vs. standard technique.

The principal objective of the study is to determine if the performance of the new technique (magnetic tracer and magnetometer) is equivalent to the performance of the standard technique (patent blue dye and radioistope; or radioisotope alone). The…

EPIK-P2: A Phase II double-blind study with an upfront, 16-week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA-related overgrowth spectrum (PROS)

This study has been transitioned to CTIS with ID 2023-508530-34-00 check the CTIS register for the current data. Primary objective:* To demonstrate the efficacy of alpelisib as measured by the proportion of participants randomized to alpelisib with…

OMIT trial: omitting therapeutic lymph node dissection in patients with stage IIIB/C melanoma and major pathological response in the index lymph node after neoadjudvant immunotherapy

To investigate whether TLND can be safely omitted in patients with macroscopic resectable stage III (B/C/D) melanoma achieving an MPR within the ILN upon neoadjuvant treatment with nivolumab in combination with ipilimumab.